126 results
8-K
EX-10.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
of receipt thereof (the “Asset Sale Reinvestment Period”) in the costs of research, development, commercialization, license, purchase, or other acquisition … of receipt thereof (the “Insurance/Condemnation Reinvestment Period”) in the costs of research, development, commercialization, license, purchase
8-K
EX-4.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
, by the relevant Asset Sale Reinvestment Deadline, in the costs of research, development, commercialization, license, purchase, or other acquisition … and techniques, inventions, research and development information, technical data, financial, marketing and business data, pricing and cost
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
8 May 24
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
7:47am
expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense … million for the first quarter of 2023. Cost of sales reflects the costs of XPOVIO units sold and the costs of products sold to our partners.
Research
8-K
EX-99.1
iajqv8
29 Feb 24
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
7:35am
8-K
EX-99.1
pu92a82ezshe 0xoa0
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
4w7hff w971zp6pml
2 Aug 23
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-99.1
bu9ecxg w9x
4 May 23
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
7:53am
8-K
j4brw3hnju80a2 g1
13 Dec 22
Other Events
5:36pm
8-K
zocr1ea4wfod c72qk
5 Dec 22
Karyopharm Announces $165 Million Private Placement
8:41am
8-K
EX-99.1
0spx034ws8i0vt405q1
5 Dec 22
Karyopharm Announces $165 Million Private Placement
8:41am